Ignite Creation Date:
2024-05-06 @ 8:18 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06331585
Status:
WITHDRAWN
Last Update Posted:
2024-04-25
First Post:
2024-03-19
Brief Title:
Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy
Sponsor:
Hetian District Peoples Hospital
Organization:
Hetian District Peoples Hospital
Study Overview
Official Title:
Phase II Trial of Low-dose Radiotherapy LDRT Affecting the Tumor Immune Microenvironment TME in Oligometastasis Oligoprogression and Oligopersistence of Non-small Cell Lung Cancer NSCLC After Immunotherapy
Status:
WITHDRAWN
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
work commitments
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this phase Ⅱ trial was to investigate the effect of low-dose radiotherapy LDRT on the tumor immune microenvironment TME in oligometastasis oligoprogression and oligopersistence of non-small cell lung cancer NSCLC after immunotherapy At least 20 participants will be enrolled in this study All will take part at Hetian District Peoples Hospital
Detailed Description:
LDRT targeting oligometastases has been shown to enhance anti-tumour immunity by reprogramming the TME thereby improving the efficacy of immunotherapy The aim of this study was to collect pathological tissues from oligometastasis oligoprogression and oligopersistence of NSCLC after immunotherapy before LDRT 5Gy5f and up to 24h after LDRT in order to apply multiplexed fluorescence immunohistochemistry mIHC for evaluation of the tumor immune microenvironment This study will be able to investigate the effect of LDRT on TME in oligometastatic lesions of NSCLC after immunotherapy and assess the efficacy and safety of LDRT
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None